Shares of biopharmaceutical company Soleno Therapeutics, Inc. (SLNO) were in the spotlight on Monday after the company ...

Soleno Therapeutics ($SLNO) stock skyrocketed up over 42% this past week on news that it has achieved a significant milestone with FDA approval ...

Soleno Therapeutics (SLNO) announced the U.S. commercial availability of VYKAT XR extended-release tablets, the company’s treatment for ...

(RTTNews) - Soleno Therapeutics, Inc. (SLNO), Monday said VYKAT XR which was approved by the Food and Drug Administration (FDA) on March 26 to treat hyperphagia in patients four years of age and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of Soleno Therapeutics SLNO have rallied 37% in the premarket hours today following the FDA approval of Vykat XR (diazoxide choline) extended-release tablets for treating hyperphagia in ...

H.C. Wainwright raised the firm’s price target on Soleno Therapeutics (SLNO) to $100 from $70 and keeps a Buy rating on the shares after the ...

Given the high price targets and potential for volatility, I recommend a "Hold" rating for SLNO, awaiting clearer market dynamics and potential for a lower entry point. The Prader-Willi Syndrome ...

In this article, we are going to take a look at where Soleno Therapeutics Inc. (NASDAQ:SLNO) stands against other stocks that outperformed broader market last week. Wall Street’s main indices ...